In summary, targeted drugs, primarily the EGFR inhibitors, have added new effective agents to the therapeutic armamentarium for NSCLC. Qualitative and quantitative survival benefit has been demonstrated with small molecules TKIs, but also anti-EGFR monoclonal antibodies, even though in an earlier stage of clinical investigation, have demonstrated promising activity that warrants further studies of these agents. Mutations in the ATP-binding site, that have been consistently associated with clinical response to TKIs [11], do not seem to predict response to anti-EGFR therapy using monoclonal antibodies such as cetuximab [4, 12]. Moreover, it has recently been reported that two patients responded to gefitinib after failure of several chemotherapy regimens and cetuximab [15]. Taken together, these findings could suggest that monoclonal antibodies and TKIs have different mechanisms of action and might be effectively combined in order to broaden their spectrum of activity.

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer / A. Sartore Bianchi, G. Cerea, I. Schiavetto, L. Giannetta, R. Ricotta, M.R. Maugeri, M. Moroni, G. Marrapese, S. Siena. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 17:suppl. 2(2006), pp. ii49-ii51. ((Intervento presentato al 12. convegno National AIOM Comference tenutosi a Roma nel 2006 [10.1093/annonc/mdj922].

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer

A. Sartore Bianchi;M. Moroni;S. Siena
Ultimo
2006

Abstract

In summary, targeted drugs, primarily the EGFR inhibitors, have added new effective agents to the therapeutic armamentarium for NSCLC. Qualitative and quantitative survival benefit has been demonstrated with small molecules TKIs, but also anti-EGFR monoclonal antibodies, even though in an earlier stage of clinical investigation, have demonstrated promising activity that warrants further studies of these agents. Mutations in the ATP-binding site, that have been consistently associated with clinical response to TKIs [11], do not seem to predict response to anti-EGFR therapy using monoclonal antibodies such as cetuximab [4, 12]. Moreover, it has recently been reported that two patients responded to gefitinib after failure of several chemotherapy regimens and cetuximab [15]. Taken together, these findings could suggest that monoclonal antibodies and TKIs have different mechanisms of action and might be effectively combined in order to broaden their spectrum of activity.
inhibitors; cetuximab
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
2006 Sartore-Bianchi et al Ann Oncol.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 44.89 kB
Formato Adobe PDF
44.89 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/349720
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact